Brain Tumor Drugs NEO100, NEO212 to Show Data
Adults with recurrent brain tumors can follow early-stage NeOnc results presented at a major November 2026 neuro-oncology meeting.
Updated on Nov. 2, 2026 in Cancer
NeOnc Technologies will present data from its NEO100 and NEO212 programs in two posters at the 31st Annual Meeting of the Society for Neuro-Oncology in Philadelphia. The poster sessions are scheduled for Friday, November 13, 2026, from 7:30 to 9:30 p.m. EST, and are of interest to people following investigational treatments for brain and central nervous system tumors.
Why it matters
The presentations give clinicians and patients with brain tumors an early look at investigational approaches that are still in early testing, so the results should be read as preliminary. Showing data at a major neuro-oncology meeting is a step toward wider scientific review, but NEO100 and NEO212 have not yet been shown to be safe or effective in larger studies.
The NEO100 poster reports updated results from a Phase 1/2a study and compassionate use experience in recurrent IDH1-mutant astrocytoma, while the NEO212 poster reports Phase 1 safety, pharmacokinetic and early activity signals in recurrent glioblastoma and brain metastases. Both are early-stage investigational studies, and the source gives no specific sample sizes or effect sizes.
The players
NeOnc Technologies Holdings, Inc.
A clinical-stage biopharmaceutical company developing therapies for central nervous system cancers, including NEO100 and NEO212, and headquartered in Calabasas, Calif.
Society for Neuro-Oncology
The professional organization whose annual meeting is a major forum for research on brain and spinal cord tumors.
University of Southern California
The institution from which NeOnc exclusively licenses a worldwide portfolio of patents and applications covering NEO100, NEO212 and related drug candidates.
The details
NEO100 is a highly purified form of perillyl alcohol that is administered intranasally, and NEO212 is an investigational oral conjugate combining temozolomide with NEO100. Temozolomide is a standard chemotherapy used in glioblastoma, and the NEO212 program is designed to address tumors that have become resistant to it. NEO212 has completed Phase 1 dose escalation and is moving toward Phase 2 development, while NEO100 remains investigational with safety and efficacy not yet established.
Timeline
November 12 to 15, 2026: 31st Annual Meeting and Education Day of the Society for Neuro-Oncology at the Pennsylvania Convention Center in Philadelphia.
Friday, November 13, 2026, 7:30 to 9:30 p.m. EST: NeOnc poster presentations at the meeting.
Health Landscape
Glioblastoma and other high-grade brain tumors remain difficult to treat, and temozolomide has been a standard chemotherapy option for many patients, which makes resistance a central problem in the field. Early-stage programs like NEO212 are being tested against this resistance, but they must pass Phase 2 and larger trials before they can be compared with current standards of care.
If you or a family member has a brain tumor, these posters are a signal of ongoing research but not a new treatment option you can request yet. Worth discussing with your oncologist whether any clinical trials of investigational agents might be appropriate for your situation.
The takeaway
The presentations add early data to the search for better options for hard-to-treat brain tumors, but NEO100 and NEO212 remain investigational. Anyone interested in clinical trials should ask their care team which studies are open and whether they fit their diagnosis.
What happens next
NeOnc's NEO100 and NEO212 posters will be presented on Friday, November 13, 2026, from 7:30 to 9:30 p.m. EST at the Society for Neuro-Oncology meeting in Philadelphia.
Further reading
For broader context on treatment approaches, explore our Cancer coverage.
More information
Visit the NeOnc Technologies website for information about its NEO100 and NEO212 programs.
